Skip to Content
Merck

A4978

Sigma-Aldrich

Alendronate sodium trihydrate

≥97% (NMR), bone resorption inhibitor, powder

Synonym(s):

4-amino-1-hydroxy-1-phosphonobutyl phosphonic acid, monosodium, MK-217

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C4H12NaNO7P2 · 3 H2O
CAS Number:
121268-17-5
Molecular Weight:
325.12
MDL number:
MFCD01748233
UNSPSC Code:
41106300
PubChem Substance ID:
24724391
NACRES:
NA.77

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Alendronate sodium trihydrate, ≥97% (NMR), powder

Quality Level

100

Assay

≥97% (NMR)

form

powder

color

white

solubility

water, double-distilled: 10 mg/mL

storage temp.

−20°C

SMILES string

[Na+].[H]O[H].[H]O[H].[H]O[H].NCCCC(O)(P(O)(O)=O)P(O)([O-])=O

InChI

1S/C4H13NO7P2.Na.3H2O/c5-3-1-2-4(6,13(7,8)9)14(10,11)12;;;;/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12);;3*1H2/q;+1;;;/p-1

InChI key

DCSBSVSZJRSITC-UHFFFAOYSA-M

Gene Information

human ... FDPS(2224)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Alendronate sodium trihydrate has been used:
  • for calcium phosphate nanoparticles (nCaP)/ bisphosphonate (BP) coating on titanium implants and analyze its osteogenic capacity
  • in osteogenic differentiation of human bone marrow stromal cells (hBMSCs) isolated from aged osteoporosis patients- and healthy-person
  • to treat osteoblast progenitor cells and osteoblasts and study their effect on osteoblast behaviors using conventional assays and simple digital image analysis

Biochem/physiol Actions

Alendronate is a nitrogen-containing bisphosphonate that is known to hinder the mevalonate pathway and limit osteoclastic function and activity. Alendronate sodium trihydrate is a bone resorption inhibitor, farnesyl diphosphate synthase inhibitor, and CD45 protein tyrosine phosphatase inhibitor.
Alendronate sodium trihydrate is a bone resorption inhibitor; farnesyl diphosphate synthase inhibitor (IC50 = 460 nM); CD45 protein tyrosine phosphatase inhibitor.

Preparation Note

Following reconstitution, it is recommended to aliquot and freeze at -20°C. Stock solutions are stable for up to 6 months at -20°C.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
105M4707V
084M4705V
022M4740V
071M4710V
120M4716V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Robert Josse et al.
Current medical research and opinion, 29(3), 205-216 (2013-01-10)
According to the 2010 Osteoporosis Canada Clinical Practice Guidelines, denosumab is a first-line option for the pharmacological management of postmenopausal osteoporosis (PMO), along with several therapeutics that may be more familiar to family practice doctors: bisphosphonates, raloxifene, teriparatide, and hormone
Mattias Ulmner et al.
Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 72(1), 76-82 (2013-09-03)
To estimate the incidence of bisphosphonate (BP)-related osteonecrosis of the jaw (BRONJ) associated with the use of oral BPs and osteonecrosis of the jaw (ONJ) not associated with current or previous medication with a BP or radiotherapy to the head
Shmuel Banai et al.
American heart journal, 165(2), 234-240 (2013-01-29)
Activation of systemic innate immunity is critical in the chain of events leading to restenosis. LABR-312 is a novel compound that transiently modulates circulating monocytes, reducing accumulation of these cells at vascular injury sites and around stent struts. The purpose
Xuefeng Hu et al.
Tissue engineering. Part A, 19(17-18), 1919-1930 (2013-04-02)
Fibrous encapsulation can impair implant osseointegration and cause implant failure but currently there are limited strategies to address this problem. Since bisphosphonates (BPs), a class of drugs widely used to treat bone diseases, was recently found to induce fibroblast apoptosis
Wei-Yih Chiu et al.
The Journal of clinical endocrinology and metabolism, 98(4), E723-E726 (2013-03-09)
Bisphosphonates effectively increase bone mineral density and reduce fracture risk in patients with osteoporosis, but there are concerns about osteonecrosis of the jaw (ONJ) and atypical femoral fractures (AFFs) in the long-term users. So far both complications have not been
View All Related Papers

Articles

지질 신호전달 연구를 위한 생체 활성 저분자

지질 신호전달 연구를 위한 생체 활성 저분자

Discover Bioactive Small Molecules for Lipid Signaling Research

Discover Bioactive Small Molecules for Lipid Signaling Research

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service